recent publications

• academic article

  • Lee, M. S., Wali, A. U., Menon, V., Berkowitz, S. D., Thompson, T. D., Califf, R. M., Topol, E. J., Granger, C. B., Hochman, J. S. The determinants of activated partial thromboplastin time, relation of activated partial thromboplastin time to clinical outcomes, and optimal dosing regimens for heparin treated patients with acute coronary syndromes: A review of gusto-iib Journal of Thrombosis and Thrombolysis  2002 14:91-101  DOI:10.1023/a:1023235926825  PMID:12714828
  • Kereiakes, D. J., Berkowitz, S. D., Lincoff, A. M., Tcheng, J. E., Wolski, K., Achenbach, R., Melsheimer, R., Anderson, K., Califf, R. M., Topol, E. J. Clinical correlates and course of thrombocytopenia during percutaneous coronary intervention in the era of abciximab platelet glycoprotein iib/iiia blockade American Heart Journal  2000 140:74-80  DOI:10.1067/mhj.2000.106615  PMID:10874266
  • McClure, M. W., Berkowitz, S. D., Sparapani, R., Tuttle, R., Kleiman, N. S., Berdan, L. G., Lincoff, A. M., Deckers, J., Diaz, R., Karsch, K. R., Gretler, D., Kitt, M., et al. Clinical significance of thrombocytopenia during a non-st-elevation acute coronary syndrome - the platelet glycoprotein iib iiia in unstable angina: Receptor suppression using integrilin therapy (pursuit) trial experience Circulation  1999 99:2892-2900  PMID:10359733
  • Mandak, J. S., Blankenship, J. C., Gardner, L. H., Berkowitz, S. D., Aguirre, F. V., Sigmon, K. N., Timmis, G. C., Gilchrist, I. C., McIvor, M., Resar, J., Weiner, B. H., George, B. S., et al. Modifiable risk factors for vascular access site complications in the impact ii trial of angioplasty with versus without eptifibatide Journal of the American College of Cardiology  1998 31:1518-1524  DOI:10.1016/s0735-1097(98)00130-2  PMID:9626829
  • Berkowitz, S. D., Sane, D. C., Sigmon, K. N., Shavender, J. H., Harrington, R. A., Tcheng, J. E., Topol, E. J., Califf, R. M., Eval c, E. Prev Isch Compl Epic Stud Grp Occurrence and clinical significance of thrombocytopenia in a population undergoing high-risk percutaneous coronary revascularization Journal of the American College of Cardiology  1998 32:311-319  DOI:10.1016/s0735-1097(98)00252-6  PMID:9708455
  • Oishi, C. S., Dlima, D. D., Morris, B. A., Hardwick, M. E., Berkowitz, S. D., Colwell, C. W. Hemodilution with other blood reinfusion techniques in total hip arthroplasty Clinical Orthopaedics and Related Research  1997 132-139  PMID:9186211
  • Berkowitz, S. D., Granger, C. B., Peiper, K. S., Lee, K. L., Gore, J. M., Simoons, M., Armstrong, P. W., Topol, E. J., Califf, R. M. Incidence and predictors of bleeding after contemporary thrombolytic therapy for myocardial infarction Circulation  1997 95:2508-2516  PMID:9184581
  • Dent, J. A., Berkowitz, S. D., Ware, J., Kasper, C. K., Ruggeri, Z. M. Identification of a cleavage site directing the immunochemical detection of molecular abnormalities in type IIA von Willebrand factor Proceedings of the National Academy of Sciences of the United States of America  1990 87:6306-6310  DOI:10.1073/pnas.87.16.6306  PMID:2385594  PMCID:PMC54522
  • Berkowitz, S. D., Dent, J., Roberts, J., Fujimura, Y., Plow, E. F., Titani, K., Ruggeri, Z. M., Zimmerman, T. S. Epitope mapping of the von Willebrand factor subunit distinguishes fragments present in normal and type IIA von Willebrand disease from those generated by plasmin Journal of Clinical Investigation  1987 79:524-531  DOI:10.1172/jci112843  PMID:2433308  PMCID:PMC424117
  • Batlle, J., Lopezfernandez, M. F., Lopezborrasca, A., Lopezberges, C., Dent, J. A., Berkowitz, S. D., Ruggeri, Z. M., Zimmerman, T. S. Proteolytic degradation of von Willebrand factor after DDAVP administration in normal individuals Blood  1987 70:173-176  PMID:3496131
  • Budde, U., Dent, J. A., Berkowitz, S. D., Ruggeri, Z. M., Zimmerman, T. S. Subunit composition of plasma von Willebrand factor in patients with the myeloproliferative syndrome Blood  1986 68:1213-1217  PMID:3535924